Solid oral dosage forms of valsartan

Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S464000, C424S489000, C514S223500, C514S223200, C514S222800

Reexamination Certificate

active

06858228

ABSTRACT:
The present invention is concerned with solid oral dosage forms of comprisinga) an active agent selected from valsartan and optionally HCTZ, andb) Pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.

REFERENCES:
patent: 3200039 (1965-08-01), Thompson, Jr.
patent: 4353887 (1982-10-01), Hess et al.
patent: 5399578 (1995-03-01), Bühlmayer et al.
patent: 5464854 (1995-11-01), dePadova
patent: 5486364 (1996-01-01), King et al.
patent: 6218414 (2001-04-01), Nisato
patent: 6294197 (2001-09-01), Wagner et al.
patent: 6485745 (2002-11-01), Wagner et al.
patent: 2421 273 (1974-11-01), None
patent: 11 490 (1980-05-01), None
patent: 70 127 (1983-01-01), None
patent: 396 335 (1990-11-01), None
patent: 9315732 (1993-08-01), None
patent: 94 09778 (1994-05-01), None
patent: 95 24901 (1995-09-01), None
patent: 95 28927 (1995-11-01), None
patent: 95 29674 (1995-11-01), None
“Hydrochlorothiazide”—Martindale 89 pp. 991-993.
“Innovatives Antihypertensives,” Therapiewoche 36, pp. 1982-1985 (1996).
Chemical Abstracts 124:220073 (1996).
DIALOG: Derwent Drug File—Abstract AN:96-09445 (1996).
DIALOG: Drug Data Report—Abstract AN 185987 (1992).
DIALOG: JICST EPlus—Abstract AN:96A0157433 (1995).
EMBASE: Abstract 96015489 (1995).
EMBASE: Abstract 96-374183 (1996).
EMBASE: Abstract AN-97-027003 (1997).
Fujimara Y. et al., “Antihypertensive effect of a combination of Valsartan . . . ”, Yakuri To Chiryo, vol. 23, No. 12, 1995, pp. 3241-3247.
Grun, A. et al., “A comparison of the efficacy and tolerability . . . ”,European Heart Journal, vol. 161, No. Sup. (1995) p. 61.
Lachman, L. et al., “The Theory and Practice of Industrial Pharmacy,” Lea & Febiger, 1986, pp. 318-320.
Markham, A., et al., “Valsartan: a review of its pharmacology and therapeutic use . . . ,” DRUGS, vol. 54, No. 2, (1997) pp. 299-311.
TOXLIT: Abstract AN-96:69983 (1995).
Fujimura et al., “Antihypertensive Effect of a Combination of Valsartan and Hydroclorothiazide, Nifedipine or Propranolol in Spontaneously Hypertensive Rats,” Japan Pharmacol Ther, vol. 23(12), pp. 3241-3247 (1995). English Translation Included.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Solid oral dosage forms of valsartan does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Solid oral dosage forms of valsartan, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Solid oral dosage forms of valsartan will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3453708

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.